SG11201602268XA - Compound for activating ampk and uses thereof - Google Patents
Compound for activating ampk and uses thereofInfo
- Publication number
- SG11201602268XA SG11201602268XA SG11201602268XA SG11201602268XA SG11201602268XA SG 11201602268X A SG11201602268X A SG 11201602268XA SG 11201602268X A SG11201602268X A SG 11201602268XA SG 11201602268X A SG11201602268X A SG 11201602268XA SG 11201602268X A SG11201602268X A SG 11201602268XA
- Authority
- SG
- Singapore
- Prior art keywords
- compound
- activating ampk
- ampk
- activating
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Toxicology (AREA)
- Pain & Pain Management (AREA)
- Biochemistry (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CN2013/084294 WO2015042821A1 (en) | 2013-09-26 | 2013-09-26 | Compound for activating ampk and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201602268XA true SG11201602268XA (en) | 2016-04-28 |
Family
ID=52741776
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201602268XA SG11201602268XA (en) | 2013-09-26 | 2013-09-26 | Compound for activating ampk and uses thereof |
Country Status (12)
| Country | Link |
|---|---|
| EP (2) | EP3050567B1 (en) |
| JP (1) | JP6254263B2 (en) |
| KR (3) | KR102221723B1 (en) |
| AU (3) | AU2013401767B2 (en) |
| CA (4) | CA3112108C (en) |
| DK (1) | DK3050567T3 (en) |
| ES (1) | ES2863173T3 (en) |
| IL (1) | IL244752B (en) |
| MY (1) | MY182801A (en) |
| PL (1) | PL3050567T3 (en) |
| SG (1) | SG11201602268XA (en) |
| WO (1) | WO2015042821A1 (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6811316B2 (en) * | 2016-10-21 | 2021-01-13 | セルバーティクス カンパニー リミテッド | A pharmaceutical composition for the prevention or treatment of diabetes and / or hyperlipidemia containing midodrine or a pharmaceutically acceptable salt thereof as an active ingredient. |
| JP7185226B2 (en) * | 2018-11-22 | 2022-12-07 | 国立大学法人 鹿児島大学 | AMPK Activator Containing 1,5-Anhydrofructose Derivative |
| KR102145438B1 (en) * | 2018-12-21 | 2020-08-18 | 연세대학교 산학협력단 | A composition for predicting a risk of neurodegenerative diseases and a method for predicting neurodegenerative diseases using the same |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RO60784A2 (en) * | 1972-11-03 | 1976-07-15 | ||
| CA2115675A1 (en) * | 1991-08-23 | 1993-03-04 | Georges H. VAN DEN BERGHE | Method for lowering blood lipid levels |
| US6342484B1 (en) * | 1993-06-30 | 2002-01-29 | Board Of Regents, The University Of Texas Systems | Method and compositions for promotion of wound treatment |
| US5589182A (en) * | 1993-12-06 | 1996-12-31 | Tashiro; Renki | Compositions and method of treating cardio-, cerebro-vascular and alzheimer's diseases and depression |
| JP3580900B2 (en) * | 1995-04-20 | 2004-10-27 | ホクレン農業協同組合連合会 | Food and feed containing, as an active ingredient, a composition mainly comprising a sugar containing an α-glucosidase inhibitor |
| JPH1135468A (en) * | 1997-07-17 | 1999-02-09 | Meiji Milk Prod Co Ltd | I type allergy-inhibiting food and inhibitor using nucleic acid and its component |
| EP1302196A1 (en) * | 2001-10-16 | 2003-04-16 | Habinger, René, Ing. Mag. | Toothpaste for promotion of intelligence |
| EP1665940A4 (en) * | 2003-09-02 | 2011-01-19 | Bbk Bio Corp | Diet food |
| US20070254853A1 (en) * | 2006-05-01 | 2007-11-01 | Board Of Regents, The University Of Texas System | Compositions and Methods for Promotion of Wound Healing |
| US8165819B2 (en) * | 2006-10-10 | 2012-04-24 | The University of Pittsburgh—Of the Commonwealth System of Higher Education | Modeling wound healing |
| WO2009014642A1 (en) * | 2007-07-19 | 2009-01-29 | Amgen Inc. | Combination of a de novo purine biosynthesis inhibitor and a cyclin dependent kinase inhibitor for the treatment of cancer |
| US20090131537A1 (en) * | 2007-11-14 | 2009-05-21 | Wille Jr John Jacob | Wound healing compositions |
| WO2010002492A1 (en) * | 2008-04-29 | 2010-01-07 | University Of Chicago | Methods of use of adenine derivatives for the treatment of diabetes and other disorders |
| CN101433540A (en) * | 2008-12-02 | 2009-05-20 | 中山大学 | Use of 3-methyl adenine in preparing medicament for treating neurodegenerative disease |
| CN101744191A (en) * | 2008-12-03 | 2010-06-23 | 许玉宝 | pumpkin vermicelli |
| WO2013061161A2 (en) * | 2011-10-28 | 2013-05-02 | Green Bcn Consulting Services Sl | New combination therapies for treating neurological disorders |
| CN102406649A (en) * | 2011-11-15 | 2012-04-11 | 张始状 | Application of five normal basic groups of human body in preparation of medicines for treating tumors |
-
2013
- 2013-09-26 JP JP2016516852A patent/JP6254263B2/en active Active
- 2013-09-26 CA CA3112108A patent/CA3112108C/en active Active
- 2013-09-26 EP EP13894637.1A patent/EP3050567B1/en active Active
- 2013-09-26 CA CA3112089A patent/CA3112089C/en active Active
- 2013-09-26 MY MYPI2016701058A patent/MY182801A/en unknown
- 2013-09-26 EP EP20194630.8A patent/EP3769766A1/en active Pending
- 2013-09-26 SG SG11201602268XA patent/SG11201602268XA/en unknown
- 2013-09-26 PL PL13894637T patent/PL3050567T3/en unknown
- 2013-09-26 CA CA3112114A patent/CA3112114C/en active Active
- 2013-09-26 ES ES13894637T patent/ES2863173T3/en active Active
- 2013-09-26 KR KR1020207010398A patent/KR102221723B1/en active IP Right Grant
- 2013-09-26 WO PCT/CN2013/084294 patent/WO2015042821A1/en active Application Filing
- 2013-09-26 KR KR1020167010883A patent/KR102101465B1/en active IP Right Grant
- 2013-09-26 CA CA2925511A patent/CA2925511C/en active Active
- 2013-09-26 KR KR1020207010397A patent/KR102248806B1/en active IP Right Grant
- 2013-09-26 AU AU2013401767A patent/AU2013401767B2/en active Active
- 2013-09-26 DK DK13894637.1T patent/DK3050567T3/en active
-
2016
- 2016-03-24 IL IL244752A patent/IL244752B/en active IP Right Grant
-
2019
- 2019-05-24 AU AU2019203668A patent/AU2019203668B2/en active Active
-
2020
- 2020-09-28 AU AU2020244377A patent/AU2020244377B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CA3112114A1 (en) | 2015-04-02 |
| KR20160060137A (en) | 2016-05-27 |
| AU2013401767B2 (en) | 2019-05-09 |
| CA2925511C (en) | 2021-05-04 |
| CA3112089A1 (en) | 2015-04-02 |
| AU2020244377A1 (en) | 2020-10-29 |
| IL244752A0 (en) | 2016-04-21 |
| MY182801A (en) | 2021-02-05 |
| KR102101465B1 (en) | 2020-04-17 |
| CA3112108C (en) | 2023-09-12 |
| KR102221723B1 (en) | 2021-03-03 |
| JP6254263B2 (en) | 2017-12-27 |
| AU2013401767A1 (en) | 2016-04-21 |
| CA3112089C (en) | 2023-04-04 |
| AU2019203668B2 (en) | 2020-09-10 |
| DK3050567T3 (en) | 2021-02-08 |
| AU2019203668A1 (en) | 2019-06-13 |
| JP2016531855A (en) | 2016-10-13 |
| KR20200041392A (en) | 2020-04-21 |
| PL3050567T3 (en) | 2021-06-14 |
| WO2015042821A1 (en) | 2015-04-02 |
| KR102248806B1 (en) | 2021-05-10 |
| KR20200041393A (en) | 2020-04-21 |
| ES2863173T3 (en) | 2021-10-08 |
| EP3769766A1 (en) | 2021-01-27 |
| CA3112108A1 (en) | 2015-04-02 |
| IL244752B (en) | 2020-01-30 |
| EP3050567A4 (en) | 2017-04-05 |
| CA2925511A1 (en) | 2015-04-02 |
| EP3050567A1 (en) | 2016-08-03 |
| AU2020244377B2 (en) | 2022-04-07 |
| CA3112114C (en) | 2023-03-28 |
| EP3050567B1 (en) | 2020-11-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL274355B (en) | Aza-pyridone compounds and uses thereof | |
| HRP20181392T1 (en) | Heterocyclic compounds and uses thereof | |
| HK1223351A1 (en) | Heterocyclic compounds and uses thereof | |
| ZA201602220B (en) | Heterocyclic compounds and uses thereof | |
| HK1219276A1 (en) | Biheteroaryl compounds and uses thereof | |
| GB201323008D0 (en) | Compounds and uses thereof | |
| EP2975028A4 (en) | Pyrazole-amide compound and medicinal uses therefor | |
| GB201300707D0 (en) | Compounds and processes | |
| GB201307233D0 (en) | Compounds and uses thereof | |
| IL244752B (en) | Compound for activating ampk and uses thereof | |
| GB201309180D0 (en) | Compounds and Their Uses | |
| HK1223307A1 (en) | Novel compounds and uses thereof | |
| GB201314610D0 (en) | Compounds and their uses | |
| GB201306248D0 (en) | Compounds and their uses | |
| ZA201601880B (en) | Hetero-transglycosylase and uses thereof | |
| GB201323005D0 (en) | Compounds and uses thereof | |
| GB201320161D0 (en) | Compounds and their uses | |
| GB201307202D0 (en) | New compounds and uses | |
| GB201307201D0 (en) | New compounds and uses | |
| GB201301734D0 (en) | New compounds and uses | |
| GB201309248D0 (en) | Compounds and combinations |